Mar. 25, 2012 A genetic finding could help explain why influenza becomes a life-threating disease to some people while it has only mild effects in others. New research led by the Wellcome Trust Sanger Institute has identified for the first time a human gene that influences how we respond to influenza infection.
People who carry a particular variant of a gene called IFITM3 are significantly more likely to be hospitalised when they fall ill with influenza than those who carry other variants, the team found. This gene plays a critical role in protecting the body against infection with influenza and a rare version of it appears to make people more susceptible to severe forms of the disease. The results are published in the journal Nature.
A central question about viruses is why some people suffer badly from an infection and others do not. IFITM3 is an important protein that protects cells against virus infection and is thought to play a critical role in the immune system's response against such viruses as H1N1 pandemic influenza, commonly known as 'swine flu'. When the protein is present in large quantities, the spread of the virus in lungs is hindered, but if the protein is defective or absent, the virus can spread more easily, causing severe disease.
"Although this protein is extremely important in limiting the spread of viruses in cells, little is known about how it works in lungs," explains Aaron Everitt, first author from the Wellcome Trust Sanger Institute. "Our research plays a fundamental part in explaining how both the gene and protein are linked to viral susceptibility."
The antiviral role of IFITM3 in humans was first suggested by studies using a genetic screen, which showed that the protein blocked the growth of influenza virus and dengue virus in cells. This led the team to ask whether IFITM3 protected mice from viral infections. They removed the IFITM3 gene in mice and found that once they contracted influenza, the symptoms became much more severe compared to mice with IFITM3. In effect, they found the loss of this single gene in mice can turn a mild case of influenza into a fatal infection.
The researchers then sequenced the IFITM3 genes of 53 patients hospitalised with influenza and found that some have a genetic mutant form of IFITM3, which is rare in normal people. This variant alters the IFITM3 gene and makes cells more susceptible to viral infection.
"Since IFITM3 appears to be a first line defender against infection, our efforts suggest that individuals and populations with less IFITM3 activity may be at increased risk during a pandemic and that IFITM3 could be vital for defending human populations against other viruses such as avian influenza virus and dengue virus" says Dr. Abraham Brass, co-senior author and Assistant Professor at the Ragon Institute of MGH, MIT and Harvard and the Gastrointestinal Unit of Massachusetts General Hospital.
This research was a collaboration between institutes in the United States and the United Kingdom. The samples for this study were obtained from the MOSAIC consortium in England and Scotland, co-ordinated from the Centre for Respiratory Infection (CRI) at Imperial College London, and the GenISIS consortium in Scotland at the Roslin Institute of University of Edinburgh. These were pivotal for the human genetics component of the work.
"Collectively, these data reveal that the action of a single antiviral protein, IFITM3, can profoundly alter the course of the flu and potentially other viruses in both human and mouse," explains Professor Paul Kellam, co-senior author from the Wellcome Trust Sanger Institute. "To fully understand how both the protein and gene control our susceptibility to viral infections, we need to study the mechanisms of the gene variant more closely.
"Our research is important for people who have this variant as we predict their immune defences could be weakened to some virus infections. Ultimately as we learn more about the genetics of susceptibility to viruses, then people can take informed precautions, such as vaccination to prevent infection."
Sir Mark Walport, director of the Wellcome Trust, said: "During the recent swine flu pandemic, many people found it remarkable that the same virus could provoke only mild symptoms in most people, while, more rarely, threatening the lives of others. This discovery points to a piece of the explanation: genetic variations affect the way in which different people respond to infection.
"This important research adds to a growing scientific understanding that genetic factors affect the course of disease in more than one way. Genetic variations in a virus can increase its virulence, but genetic variations in that virus's host -- us -- matter greatly as well."
Other social bookmarking and sharing tools:
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
- Aaron R. Everitt, Simon Clare, Thomas Pertel, Sinu P. John, Rachael S. Wash, Sarah E. Smith, Christopher R. Chin, Eric M. Feeley, Jennifer S. Sims, David J. Adams, Helen M. Wise, Leanne Kane, David Goulding, Paul Digard, Verneri Anttila, J. Kenneth Baillie, Tim S. Walsh, David A. Hume, Aarno Palotie, Yali Xue, Vincenza Colonna, Chris Tyler-Smith, Jake Dunning, Stephen B. Gordon, K. Everingham, H. Dawson, D. Hope, P. Ramsay, T. S. Walsh (Local Lead Investigator), A. Campbell, S. Kerr, D. Harrison, K. Rowan, J. Addison, N. Donald, S. Galt, D. Noble, J. Taylor, N. Webster (Local Lead Investigator), I. Taylor (Local Lead Investigator), J. Aldridge (Local Lead Investigator), R. Dornan, C. Richard, D. Gilmour, R. Simmons (Local Lead Investigator), R. White (Local Lead Investigator), C. Jardine, D. Williams (Local Lead Investigator), M. Booth (Local Lead Investigator), T. Quasim, V. Watson, P. Henry, F. Munro, L. Bell, J. Ruddy (Local Lead Investigator), S. Cole (Local Lead Investigator), J. Southward, P. Allcoat, S. Gray, M. McDougall (Local Lead Investigator), J. Matheson, J. Whiteside (Local Lead Investigator), D. Alcorn, K. Rooney (Local Lead Investigator), R. Sundaram, G. Imrie (Local Lead Investigator), J. Bruce, K. McGuigan, S. Moultrie (Local Lead Investigator), C. Cairns (Local Lead Investigator), J. Grant, M. Hughes, C. Murdoch (Local Lead Investigator), A. Davidson (Local Lead Investigator), G. Harris, R. Paterson, C. Wallis (Local Lead Investigator), S. Binning (Local Lead Investigator), M. Pollock, J. Antonelli, A. Duncan, J. Gibson, C. McCulloch, L. Murphy, C. Haley, G. Faulkner, T. Freeman, D. A. Hume, J. K. Baillie (Principal Investigator), D. Chaussabel, W. E. Adamson, W. F. Carman, C. Thompson, M. C. Zambon, P. Aylin, D. Ashby, W. S. Barclay, S. J. Brett, W. O. Cookson, L. N. Drumright, J. Dunning, R. A. Elderfield, L. Garcia-Alvarez, B. G. Gazzard, M. J. Griffiths, M. S. Habibi, T. T. Hansel, J. A. Herberg, A. H. Holmes, T. Hussell, S. L. Johnston, O. M. Kon, M. Levin, M. F. Moffatt, S. Nadel, P. J. Openshaw, J. O. Warner, S. J. Aston, S. B. Gordon, A. Hay, J. McCauley, A. O’Garra, J. Banchereau, A. Hayward, P. Kellam, J. K. Baillie, D. A. Hume, P. Simmonds, P. S. McNamara, M. G. Semple, R. L. Smyth, J. S. Nguyen-Van-Tam, L.-P. Ho, A. J. McMichael, P. Kellam, Rosalind L. Smyth, Peter J. Openshaw, Gordon Dougan, Abraham L. Brass, Paul Kellam. IFITM3 restricts the morbidity and mortality associated with influenza. Nature, 2012; DOI: 10.1038/nature10921
Note: If no author is given, the source is cited instead.